The financials
Phibro Animal Health Corporation by the numbers
Phibro Animal Health Corporation (PAHC) reported revenue of $384M in Q3 2026 (quarter ended March 31, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 33% and net income of $24M (6.3% of revenue). For the full year FY2025, revenue was $1.30B (+27% year on year) and net income $48M. Its largest product in 2026-Q1 was Medicated Feed Additives And Others at $206M, 54% of the disclosed total, just ahead of Mineral Nutrition at 19%.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $384M | $348M | +10% |
| Gross profit | $126M | $105M | +20% |
| Operating income | $45M | $34M | +33% |
| Net income | $24M | $21M | +15% |
| Diluted EPS | $0.59 | $0.51 | +16% |
| Product | Revenue | Share |
|---|---|---|
| Medicated Feed Additives And Others | $206M | 54% |
| Mineral Nutrition | $73M | 19% |
| Nutritional Specialties | $47M | 12% |
| Vaccines | $39M | 10% |
| Performance Products | $19M | 4.9% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $383.5M (+2.6%)
Vaccines grew +16% year on yearPerformance Products -17% year on year
Segment Latestquarter on quarteryear on year
- Medicated Feed Additives And Others$205.8M$205.8MQoQ +1.8%year on year +13%+1.8%+13%
- Mineral Nutrition$73.4M$73.4MQoQ +6.5%year on year +9.9%+6.5%+9.9%
- Nutritional Specialties$46.8M$46.8MQoQ -6.8%year on year +8.0%-6.8%+8.0%
- Vaccines$38.6M$38.6MQoQ +2.6%year on year +16%+2.6%+16%
- Performance Products$18.9M$18.9MQoQ +26%year on year -17%+26%-17%
Drug Manufacturers - Specialty & Generic
Ranks #11 of 28 by Smart Score